These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35549809)

  • 1. Risk of severe COVID-19 in patients with inflammatory rheumatic diseases treated with immunosuppressive therapy in Scotland.
    McKeigue PM; Porter D; Hollick RJ; Ralston SH; McAllister DA; Colhoun HM
    Scand J Rheumatol; 2023 Jul; 52(4):412-417. PubMed ID: 35549809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.
    Gianfrancesco M; Hyrich KL; Al-Adely S; Carmona L; Danila MI; Gossec L; Izadi Z; Jacobsohn L; Katz P; Lawson-Tovey S; Mateus EF; Rush S; Schmajuk G; Simard J; Strangfeld A; Trupin L; Wysham KD; Bhana S; Costello W; Grainger R; Hausmann JS; Liew JW; Sirotich E; Sufka P; Wallace ZS; Yazdany J; Machado PM; Robinson PC;
    Ann Rheum Dis; 2020 Jul; 79(7):859-866. PubMed ID: 32471903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of COVID-19 in Patients With Rheumatic Diseases Treated With Targeted Immunosuppressive Drugs: What Can We Learn From Observational Data?
    Favalli EG; Monti S; Ingegnoli F; Balduzzi S; Caporali R; Montecucco C
    Arthritis Rheumatol; 2020 Oct; 72(10):1600-1606. PubMed ID: 32506699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy.
    Spila Alegiani S; Crisafulli S; Giorgi Rossi P; Mancuso P; Salvarani C; Atzeni F; Gini R; Kirchmayer U; Belleudi V; Kurotschka PK; Leoni O; Ludergnani M; Ferroni E; Baracco S; Massari M; Trifirò G;
    Rheumatology (Oxford); 2021 Oct; 60(SI):SI25-SI36. PubMed ID: 33856453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study.
    Ingrasciotta Y; Jin Y; Foti SS; Landon JE; Tari M; Mattace-Raso F; Kim SC; Trifirò G
    Clin Rheumatol; 2023 Apr; 42(4):1047-1059. PubMed ID: 36534353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of the mRNA-1273 and ChAdOx1 nCoV-19 vaccines in Asian patients with autoimmune rheumatic diseases under biologic and/or conventional immunosuppressant treatments.
    Liao HT; Tung HY; Chou CT; Tsai HC; Yen YN; Tsai CY
    Scand J Rheumatol; 2022 Nov; 51(6):500-505. PubMed ID: 35638589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and risk factors of herpes zoster infection in patients with rheumatic diseases not receiving biologic or targeted therapies.
    Mok CC; Ho LY; Tse SM; Chan KL; To CH
    Clin Rheumatol; 2023 Apr; 42(4):1019-1026. PubMed ID: 36385600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 in DMARD-treated patients with inflammatory rheumatic diseases: Insights from an analysis of the World Health Organization pharmacovigilance database.
    Dernoncourt A; Schmidt J; Duhaut P; Liabeuf S; Gras-Champel V; Masmoudi K; Bennis Y; Batteux B
    Fundam Clin Pharmacol; 2022 Feb; 36(1):199-209. PubMed ID: 33973280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?
    Santos CS; Férnandez XC; Moriano Morales C; Álvarez ED; Álvarez Castro C; López Robles A; Pérez Sandoval T
    RMD Open; 2021 Jan; 7(1):. PubMed ID: 33455920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination.
    Andreica I; Blazquez-Navarro A; Sokolar J; Anft M; Kiltz U; Pfaender S; Vidal Blanco E; Westhoff T; Babel N; Stervbo U; Baraliakos X
    RMD Open; 2022 Sep; 8(2):. PubMed ID: 36104115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations.
    Favalli A; Favalli EG; Gobbini A; Zagato E; Bombaci M; Maioli G; Pesce E; Donnici L; Gruarin P; Biggioggero M; Curti S; Manganaro L; Marchisio E; Bevilacqua V; Martinovic M; Fabbris T; Sarnicola ML; Crosti M; Marongiu L; Granucci F; Notarbartolo S; Bandera A; Gori A; De Francesco R; Abrignani S; Caporali R; Grifantini R
    Front Immunol; 2022; 13():873195. PubMed ID: 35757699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial disease modifying antirheumatic drugs and prednisolone prescriptions for patients with rheumatoid arthritis: a 15-year study.
    Osiri M; Akkasilpa S; Deesomchok U
    J Med Assoc Thai; 2000 Mar; 83(3):217-24. PubMed ID: 10808674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases.
    Pablos JL; Abasolo L; Alvaro-Gracia JM; Blanco FJ; Blanco R; Castrejón I; Fernandez-Fernandez D; Fernandez-Gutierrez B; Galindo-Izquierdo M; Gonzalez-Gay MA; Manrique-Arija S; Mena Vázquez N; Mera Varela A; Retuerto M; Seijas-Lopez A;
    Ann Rheum Dis; 2020 Sep; 79(9):1170-1173. PubMed ID: 32532753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Kerschbaumer A; Sepriano A; Bergstra SA; Smolen JS; van der Heijde D; Caporali R; Edwards CJ; Verschueren P; de Souza S; Pope JE; Takeuchi T; Hyrich KL; Winthrop KL; Aletaha D; Stamm TA; Schoones JW; Landewé RBM
    Ann Rheum Dis; 2023 Jan; 82(1):95-106. PubMed ID: 36368906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of Treatment Change Among Patients with Rheumatoid Arthritis Treated with TNF Inhibitors as First-Line Biologic Agent in the USA: A Cohort Study from Longitudinal Electronic Health Records.
    Jin Y; Landon JE; Krueger W; Liede A; Desai RJ; Kim SC
    BioDrugs; 2022 Jul; 36(4):521-535. PubMed ID: 35771381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial.
    Rantalaiho V; Korpela M; Laasonen L; Kautiainen H; Järvenpää S; Hannonen P; Leirisalo-Repo M; Blåfield H; Puolakka K; Karjalainen A; Möttönen T;
    Arthritis Res Ther; 2010; 12(3):R122. PubMed ID: 20576092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes.
    Montero F; Martínez-Barrio J; Serrano-Benavente B; González T; Rivera J; Molina Collada J; Castrejón I; Álvaro-Gracia J
    Rheumatol Int; 2020 Oct; 40(10):1593-1598. PubMed ID: 32794113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study.
    Pablos JL; Galindo M; Carmona L; Lledó A; Retuerto M; Blanco R; Gonzalez-Gay MA; Martinez-Lopez D; Castrejón I; Alvaro-Gracia JM; Fernández Fernández D; Mera-Varela A; Manrique-Arija S; Mena Vázquez N; Fernandez-Nebro A; ;
    Ann Rheum Dis; 2020 Dec; 79(12):1544-1549. PubMed ID: 32796045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline use of hydroxychloroquine or immunosuppressive drugs and the risk of coronavirus disease 2019.
    Kim JW; Kwak SG; Lee H; Kim SK; Choe JY; Park SH
    Korean J Intern Med; 2022 May; 37(3):673-680. PubMed ID: 33706472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry.
    Strangfeld A; Schäfer M; Gianfrancesco MA; Lawson-Tovey S; Liew JW; Ljung L; Mateus EF; Richez C; Santos MJ; Schmajuk G; Scirè CA; Sirotich E; Sparks JA; Sufka P; Thomas T; Trupin L; Wallace ZS; Al-Adely S; Bachiller-Corral J; Bhana S; Cacoub P; Carmona L; Costello R; Costello W; Gossec L; Grainger R; Hachulla E; Hasseli R; Hausmann JS; Hyrich KL; Izadi Z; Jacobsohn L; Katz P; Kearsley-Fleet L; Robinson PC; Yazdany J; Machado PM;
    Ann Rheum Dis; 2021 Jul; 80(7):930-942. PubMed ID: 33504483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.